Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes

Atherosclerosis

Volumn 243, Issue 1, 2015, Pages 328-333

  Thompson, Gilbert R ^a   Seed, Mary ^a   Naoumova, Rossi P ^b   Neuwirth, Clare ^a   Walji, Shahenaz ^c   Aitman, Timothy J ^d   Scott, James ^a   Myant, Nicolas B ^e   Soutar, Anne K ^f  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e MEDICAL RESEARCH COUNCIL   (United Kingdom)

^f MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

Author keywords

Aortic stenosis; Apheresis; ARH mutations; LDLR mutations; Statins

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AORTA STENOSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; HOMOZYGOTE; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED KINGDOM; ADOLESCENT; AORTIC VALVE STENOSIS; APHERESIS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; GENETICS; GREAT BRITAIN; HYPERLIPOPROTEINEMIA TYPE II; MIDDLE AGED; MUTATION; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTICHOLESTEREMIC AGENTS; AORTIC VALVE STENOSIS; BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; GREAT BRITAIN; HOMOZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MODELS, STATISTICAL; MUTATION; RECEPTORS, LDL; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84943329834     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.09.029     Document Type: Article

References (41)

1. Anitschkow N., Chalatow S. Classics in arteriosclerosis research: on experimental cholesterin steatosis and its significance in the origin of some pathological processes, translated by Mary Z. Pelias. Arteriosclerosis 1913, 1983(3):178-182.
2. Webb J.C., Sun X.M., McCarthy S.N., et al. Characterization of mutations in the low density lipoprotein (LDL)-receptor gene in patients with homozygous familial hypercholesterolemia, and frequency of these mutations in FH patients in the United Kingdom. J. Lipid Res. 1992, 33:689-698.
3. Rallidis L., Naoumova R.P., Thompson G.R., Nihoyannopoulos P. Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart 1998, 80:583-590.
4. Muller C. Angina pectoris in hereditary xanthomatosis. Arch. Intern. Med. 1939, 64:675-700.
5. Goldstein J.L., Brown M.S. The LDL receptor locus and the genetics of familial hypercholesterolemia. Annu. Rev. Genet. 1979, 13:259-289.
6. Goldberg A.C., Hopkins P.N., Toth P.P., et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients. J. Clin. Lipidol. 2011, 5:S1-S8.
7. Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus statement of the European Atherosclerosis Society. Eur. Heart J. 2013, 34:3478-3490.
8. Sjouke B., Kusters M., Kindt I., et al. Homozygous autosomal dominant hypercholesterolemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur. Heart J. 2015, 36:560-565.
9. Thompson G.R., Miller J.P., Breslow J.L. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. Br. Med. J. Clin. Res. Ed. 1985, 291:1671-1673.
10. Raal F.J., Pilcher G.J., Panz V.R., et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011, 124:2202-2207.
11. Thompson G.R. Managing homozygous familial hypercholesterolaemia from cradle to grave. Atheroscler. Suppl. 2015, 18:16-20.
12. Stefanutti C., Thompson G.R. Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. Curr. Atheroscler. Rep. 2014, 17:465-474.
13. Myant N.B. Plasma cholesterol as a cause of coronary heart disease (CHD); the cholesterol-CHD hypothesis. Wellcome Witnesses to Twentieth Century Medicine 2006, vol. 27:xxi-xxv. The Wellcome Trust, London. L.A. Reynolds, E.M. Tansey (Eds.).
14. Thompson G.R., Lowenthal R., Myant N.B. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1975, 1:1208-1211.
15. Soutar A.K., Knight B.L., Patel D.D. Identification of a point mutation in growth factor repeat C of the low density lipoprotein-receptor gene in a patient with homozygous familial hypercholesterolemia that affects ligand binding and intracellular movement of receptors. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:4166-4170.
16. Webb J.C., Sun X.M., Patel D.D., McCarthy S.N., Knight B.L., Soutar A.K. Characterization of two new point mutations in the low density lipoprotein receptor genes of an English patient with homozygous familial hypercholesterolemia. J. Lipid Res. 1992, 33:689-698.
17. Sun X.M., Webb J.C., Gudnason V., et al. Characterization of deletions in the LDL receptor gene in patients with familial hypercholesterolemia in the United Kingdom. Arterioscler. Thromb. 1992, 12:762-770.
18. Feher M.D., Webb J.C., Patel D.D., et al. Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia. Atherosclerosis 1993, 103:171-180.
19. Bourbon M., Fowler A.M., Sun X.M., Soutar A.K. Inheritance of two different alleles of the low-density lipoprotein (LDL)-receptor gene carrying the recurrent Pro664Leu mutation in a patient with homozygous familial hypercholesterolaemia. Clin. Genet. 1999, 56:225-231.
20. Eden E.R., Patel D.D., Sun X.M., et al. Restoration of LDL receptor function in cells from patients with autosomal recessive hypercholesterolemia by retroviral expression of ARH1. J. Clin. Invest 2002, 110:1695-1702.
21. Gudnason V., Muller D.P., Lloyd J.K., Humphries S.E. Response to drugs and diet in a compound heterozygote for familial hypercholesterolaemia. Arch. Dis. Child. 1995, 73:538-540.
22. Naoumova R.P., Neuwirth C., Lee P., et al. Autosomal recessive hypercholesterolaemia: long-term follow up and response to treatment. Atherosclerosis 2004, 174:165-172.
23. Nauomova R.P., Thompson G.R., Soutar A.K. Current management of severe homozygous hypercholesterolaemias. Curr. Opin. Lipidol. 2004, 15:413-422.
24. Thompson G.R., Myant N.B., Kilpatrick D., et al. Assessment of long-term plasma exchange for familial hypercholesterolaemia. Br. Heart J. 1980, 43:680-688.
25. Allen J.M., Thompson G.R., Myant N.B., Steiner R., Oakley C.M. Cardiovascular complications of homozygous familial hypercholesterolaemia. Br. Heart J. 1980, 44:36l-368.
26. Marais A.D., Naoumova R.P., Firth J.C., et al. Decreased production of low density lipoprotein production by atorvastatin after apheresis in homozygous familial hypercholesterolaemia. J. Lipid Res. 1997, 38:2071-2078.
27. Lewis B., Myant N.B. Studies in the metabolism of cholesterol in subjects with normal plasma cholesterol levels and in patients with essential hypercholesterolaemia. Clin. Sci. 1967, 32:201-213.
28. Johnston I.D., Davis J.A., Moutafis C.D., Myant N.B. Ileal bypass in the management of familial hypercholesterolaemia. Proc. R. Soc. Med. 1967, 60:16-18.
29. Barbir M., Khagani A., Kehely A., et al. Normal levels of lipoproteins including lipoprotein (a) after liver-heart transplantation in a patient with homozygous familial hypercholesterolaemia. Q. J. Med. 1992, 85:807-812.
30. Hendry W.G., Seed M. Homozygous familial hypercholesterolaemia with supravalvar aortic stenosis treated by surgery. J. R. Soc. Med. 1985, 78:334-335.
31. Tosi I., Toledo-Leiva P., Neuwirth C., Naoumova R.P., Soutar A.K. Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic. Atheroscleosis 2007, 194:102-111.
32. Thompson GR, Seed M, Naoumova RP, et al., Demographic, genetic, lipidological and cardiovascular features of the Hammersmith Hospital cohort of familial hypercholesterolaemia homozygotes. Data in Brief (submitted).
33. Ibrahim M., El-Hamamsy I., Barbir M., Yacoub M.H. Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively. J. Cardiovasc. Transl. Res. 2012, 5:351-358.
34. Pisciotta L., Oliva C.P., Pes G.M., et al. Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison. Atherosclerosis 2006, 188:398-405.
35. Real J.T., Chaves F.J., Martinez-Uso I., et al. Importance of HDL cholesterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia. Eur. Heart J. 2001, 22:465-471.
36. Seed M., Hopplicher F., Reaveley D., et al. Relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N. Engl. J. Med. 1990, 322:1494-1499.
37. Lefort B., Saheb S., Bruckert E., et al. Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia. Atherosclerosis 2015, 239:158-162.
38. Cuchel M., Bruckert E., Ginsberg H., et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur. Heart J. 2014, 35:2146-2157.
39. Wiegman A., Gidding S.S., Watts G.F., et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur. Heart J. 2015, 36:2425-2437.
40. Cuchel M., Meagher E.A., du Toit Theron H., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46.
41. Walji S., Neuwirth C., Thompson G.R. Lipoprotein apheresis for the treatment of familial hypercholesterolaemia. Clin. Lipidol. 2013, 8:573-586.